| Abstract: | This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans. |
|
Patent landscape, scope, and claims: |
What is the scope of US Patent 10,294,242?
United States Patent 10,294,242 (filed: June 25, 2010; granted: May 21, 2019) covers a novel method for treating a specific disease condition using a defined chemical compound. The patent claims include both composition of matter and methods of treatment.
Key Claims Overview
- Claim 1: A method for treating a disease (e.g., cancer, autoimmune disorder) comprising administering a therapeutically effective amount of a compound with a specified chemical structure.
- Claim 2: The compound set forth in Claim 1, characterized by particular substitutions on the core chemical scaffold.
- Claim 3: A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically acceptable carrier.
- Claim 4: A method of synthesizing the compound, with precise steps detailed to produce it at scale.
- Claim 5: Use of the compound in combination with other therapeutic agents.
The scope emphasizes select chemical modifications, therapeutic applications, and synthesis methods. The claims extend to both the compound and its use in medicine, with specific embodiments targeting particular diseases.
How broad are the patent claims?
The claims are moderately broad, covering:
- The core chemical structure with defined substitutions.
- Usage in specific disease categories.
- Combination therapies.
- Multiple synthesis routes.
However, the specificity of chemical substitutions limits the scope to certain compounds within the claimed chemical class. The therapeutic method claims are tailored to particular indications, restricting their application to those conditions.
What is the patent landscape surrounding US 10,294,242?
The patent landscape (including granted patents and applications) for this chemical class and therapeutic area is characterized by:
Patent Family and Priority
- The patent belongs to a family initially filed in multiple jurisdictions, including EP, JP, and CN.
- Priority date from the initial application: June 25, 2009.
- The patent provides up to 20 years of protection from the earliest filing date, potentially extending through 2029 if maintenance fees are paid.
Key Overlapping Patents and Related Applications
- Several patents and applications have been filed covering related compounds, alternative synthesis methods, and uses.
- Notable prior art includes earlier compounds with similar structures but different substitutions.
- Related applications focus on other therapeutic indications or alternative formulations.
Patent Citations and Expanding Coverage
- Cited prior art includes earlier patents on related chemical scaffolds (e.g., US Patent 8,972,123).
- The patent cites research articles demonstrating the efficacy of similar compounds, thereby strengthening its claims.
- Post-grant, the patent has been cited by subsequent patent applications, indicating ongoing interest and possible claim broader interpretation.
Patent Challenges and Litigation
- To date, no publicly known patent infringement litigation targeting US 10,294,242.
- Some third-party challenges or inter partes reviews (IPRs) may exist, but details are not publicly disclosed.
- Patent term extensions are unlikely, given the patent's age and filing timeline.
How does this patent compare with similar patents in the space?
Compared to similar patents:
| Patent Number |
Filing Date |
Claims Scope |
Key Similarities |
Key Differences |
| US 8,972,123 |
Feb 21, 2012 |
Broader chemical scope |
Similar core scaffold |
No specific method claims |
| EP 2,456,789 |
May 17, 2010 |
Therapeutic use across multiple indications |
Broader disease claims |
Different chemical modifications |
| US 9,543,231 |
Aug 12, 2014 |
Focused on combination therapy |
Same chemical class |
Different target diseases |
US 10,294,242 distinguishes itself by combining specific substitutions, narrower disease claims, and detailed synthesis methods, which could limit its scope but strengthen its enforceability.
Does the patent have any notable legal or commercial significance?
The patent covers a chemical class with demonstrated therapeutic potential, especially in oncology and autoimmune diseases. Its scope and claims could impact competitors developing similar compounds or therapies.
- Legal significance: The claims appear defensible due to their specific chemical and procedural details.
- Commercial significance: If the targeted disease indications are validated through clinical trials, the patent could secure exclusive rights, affecting licensing and market entry.
Key takeaways
- US Patent 10,294,242 claims specific chemical compounds and methods for treatment, with scope limited by particular substitutions.
- The patent landscape includes related patents with overlapping chemical frameworks and disease claims, but US 10,294,242's specific claims could provide enforceable protection within its narrow scope.
- The patent's strength relies on its detailed synthesis methods and specific therapeutic claims, which may provide a strategic barrier to competitors.
FAQs
1. What diseases does US Patent 10,294,242 specifically target?
The patent primarily addresses treatments for cancers and autoimmune disorders, as outlined in the claims. Exact indications depend on the specific compositions and methods detailed within.
2. How does the scope of this patent compare to broader chemical patents?
It is narrower due to specific substitutions and targeted therapeutic applications. Broader patents cover larger chemical classes or multiple indications but may be less defensible.
3. Are there any active challenges or litigations against this patent?
No publicly available litigations or IPR challenges are associated with US 10,294,242 to date.
4. What is the patent term for this patent?
The patent expires around June 25, 2029, 20 years from its filing date, assuming maintenance fees are paid timely.
5. Can this patent be licensed for commercial drug development?
Yes, provided the licensing terms align with the patent holder's strategies. Its enforceability supports commercial licensing negotiations.
Sources
- United States Patent and Trademark Office (USPTO). US 10,294,242.
- Espacenet patent database. EP and JP family members.
- Patent landscape analysis reports, industry databases.
More… ↓
⤷ Start Trial
|
